ELMO2 Antibody

What is ELMO2 and what cellular functions does it regulate?

ELMO2 (Engulfment and Cell Motility Protein 2) is a cytosolic protein that plays a crucial role in regulating cytoskeletal dynamics. It participates in numerous cellular processes including cell motility and phagocytosis of apoptotic cells . ELMO2 forms functionally important interactions with several proteins, most notably with DOCK180 (Dedicator of Cytokinesis 180) and RhoG in a GTP-dependent manner. These interactions create a ternary complex that is essential for Rac1 activation .

The ELMO2-DOCK180-Rac1 signaling pathway is vital for integrin-mediated cell spreading and neurite outgrowth induced by nerve growth factor . More recent research has revealed ELMO2's importance in insulin-dependent Glut4 membrane translocation and in myoblast fusion during muscle development and regeneration . The protein's ability to orchestrate complex signaling networks makes it a significant focus in research on developmental biology and cancer metastasis, where cell motility is a key factor .

What are the structural domains of ELMO2 and how do they affect its function?

ELMO2 contains several distinct functional domains that dictate its interactions and regulatory capabilities:

• N-terminal domain (NTD) composed of:

  • RAS-Binding Domain (RBD): Interacts with small GTPases like RHOG and ARL4A

  • ELMO Inhibitory Domain (EID): Regulates ELMO2's conformational state

  • ELMO domain: Contributes to protein-protein interactions

• C-terminal region containing:

  • PH (Pleckstrin Homology) domain: Mediates protein-protein interactions and potentially membrane targeting

ELMO2 exists in two conformational states: closed and open. In the closed conformation, the N-terminal domain makes direct contact with the PH domain of ELMO2 and the DHR-2 domain of DOCK, resulting in an inhibited state . In the open conformation, the NTD undergoes a ~120-degree rotation that releases inhibitory contacts and exposes the RBD for binding to GTPases and allows the DHR-2 domain to activate RAC . This conformational switching mechanism is critical for regulating ELMO2's signaling output in vivo.

Mutations in these domains can significantly affect function. For example, the L43A mutation in the RBD abolishes binding to RHOG or ARL4A, while the I196D mutation in the EID favors the open conformation that enhances signaling .

What types of ELMO2 antibodies are available for research use?

Several types of ELMO2 antibodies are available for research applications, varying in host species, clonality, and conjugation options:

• Monoclonal antibodies:

  • Mouse monoclonal IgG1 kappa light chain antibodies (e.g., C-12) that detect ELMO2 from mouse, rat, and human origins

• Polyclonal antibodies:

  • Goat polyclonal antibodies recognizing human, rat, and mouse ELMO2

• Available conjugations include:

  • Non-conjugated primary antibodies

  • Agarose-conjugated for immunoprecipitation

  • Horseradish peroxidase (HRP)-conjugated for enhanced chemiluminescence detection

  • Fluorescent conjugates including phycoerythrin (PE), fluorescein isothiocyanate (FITC), and various Alexa Fluor® options

These antibodies have been validated for multiple applications including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), flow cytometry (Flow Cyt), immunohistochemistry on paraffin sections (IHC-P), and enzyme-linked immunosorbent assay (ELISA) .

How are ELMO2 antibodies used to study insulin-dependent glucose transport?

ELMO2 antibodies have been instrumental in uncovering ELMO2's role in insulin-dependent glucose transport. Research demonstrates that ELMO2 is a novel regulator of insulin-dependent Glut4 membrane translocation, which is essential for glucose homeostasis .

Methodologically, researchers use ELMO2 antibodies in multiple ways:

• Co-immunoprecipitation assays: Anti-ELMO2 antibodies are used to detect ELMO2 in anti-ClipR-59 immunoprecipitates from 3T3-L1 adipocytes, revealing a complex between ClipR-59, ELMO2, and Akt . This technique helps elucidate the protein interactions that regulate glucose transport.

• Western blotting: After isolating plasma membrane (PM) fractions from insulin-treated cells, anti-ELMO2 antibodies are used to analyze ELMO2's translocation to the membrane, correlating with Glut4 translocation .

• Validation of knockdown experiments: When studying the effects of ELMO2 suppression via shRNA, anti-ELMO2 antibodies confirm the efficacy of knockdown, showing approximately 50% reduction in ELMO2 expression .

• Rescue experiments: After reintroducing shRNA-resistant ELMO2 into knockdown cells, antibodies confirm the restored expression and correlate it with rescued Glut4 membrane translocation and glucose uptake .

These applications have revealed that ELMO2 enhances the association of ClipR-59 with Akt, which is critical for insulin-stimulated Glut4 translocation to the plasma membrane and subsequent glucose uptake in muscle cells .

What role does ELMO2 play in muscle development and regeneration?

ELMO2 antibodies have helped establish that ELMO proteins are essential for myoblast fusion, a critical process in muscle development and regeneration. Research using ELMO2 antibodies in various mouse models has demonstrated:

These findings, facilitated by ELMO2 antibodies, highlight the potential of modulating ELMO2 conformation as a therapeutic approach for improving muscle regeneration in conditions like muscular dystrophies or age-related sarcopenia.

How do ELMO2 antibodies help investigate cell migration and cytoskeletal dynamics?

ELMO2 antibodies are valuable tools for studying cell migration and cytoskeletal dynamics in various cellular contexts:

• Visualizing ELMO2 localization during cell migration:

  • Immunofluorescence using anti-ELMO2 antibodies shows dynamic redistribution of ELMO2 to the leading edge of migrating cells, correlating with areas of active cytoskeletal remodeling .

  • This visualization helps establish ELMO2's role in directional migration and response to chemotactic signals.

• Investigating protein complexes involved in cytoskeletal regulation:

  • Co-immunoprecipitation with ELMO2 antibodies identifies interacting partners like DOCK1 and CRK that are critical for Rac activation and subsequent actin cytoskeleton reorganization .

  • These experiments have helped establish that ELMO2 enhances the guanine nucleotide exchange factor (GEF) activity of DOCK1, activating Rac Rho small GTPases .

• Examining ELMO2's role in phagocytosis:

  • ELMO2 antibodies are used to track the protein during engulfment of apoptotic cells, revealing its importance in the cytoskeletal rearrangements required for efficient phagocytosis .

  • This has applications in understanding immune system function and clearance of cellular debris.

• Studying RHOG-dependent ELMO2 activation:

  • Using NMR spectroscopy in conjunction with ELMO2 antibodies, researchers have determined that RHOG binds to wild-type ELMO2 with an affinity of 10.3 μM, while the L43A mutant shows no measurable binding .

  • This methodology helps understand the molecular mechanisms underlying ELMO2 activation and subsequent cytoskeletal changes.

By employing ELMO2 antibodies in these diverse applications, researchers can dissect the complex signaling networks controlling cell movement, invasion, and phagocytosis, which have implications for cancer metastasis, developmental processes, and immune function.

What are the optimal conditions for using ELMO2 antibodies in Western blotting?

For optimal Western blotting results with ELMO2 antibodies, researchers should consider the following methodological details:

• Sample preparation:

  • ELMO2 has a molecular weight of approximately 80 kDa, so use appropriate percentage (8-10%) SDS-PAGE gels for optimal separation .

  • When investigating membrane translocation, separate plasma membrane fractions from cytosolic fractions before loading .

  • Include appropriate controls: total cell lysates to confirm expression levels and loading controls such as syntaxin 4 for membrane fractions .

• Antibody selection and dilution:

  • For mouse, rat, or human samples, mouse monoclonal antibodies (e.g., C-12) or goat polyclonal antibodies have been validated .

  • Starting dilution recommendations: 1:500 to 1:1000 for primary antibodies, adjusted based on signal intensity.

  • Consider using HRP-conjugated versions for direct detection without secondary antibodies .

• Detection optimization:

  • ELMO2 co-precipitates with interaction partners like ClipR-59 and Akt; to detect these interactions, strip and reprobe membranes with respective antibodies .

  • In knockout/knockdown validation experiments, expect approximately 50% reduction in band intensity with partial knockdown .

  • When analyzing rescue experiments with shRNA-resistant ELMO2, Western blotting can confirm successful re-expression before functional assays .

• Data interpretation:

  • When analyzing complex formation, compare band intensities between immunoprecipitated samples and input controls to assess interaction strength .

  • For mutant ELMO2 proteins (e.g., RBD or EID mutations), band intensities should be comparable to wild-type unless expression is affected .

These optimized conditions enable reliable detection of ELMO2 and its interacting partners in various experimental contexts, facilitating research on its roles in cytoskeletal dynamics, insulin signaling, and muscle regeneration.

How can researchers optimize ELMO2 antibody-based immunoprecipitation experiments?

Optimizing immunoprecipitation (IP) experiments with ELMO2 antibodies requires careful consideration of several technical aspects:

• Antibody selection:

  • Choose antibodies specifically validated for IP applications .

  • Consider using agarose-conjugated ELMO2 antibodies for direct pull-down without protein A/G beads .

  • For co-IP of specific complexes, selecting antibodies recognizing epitopes away from interaction surfaces improves complex preservation.

• Lysis buffer composition:

  • For ELMO2 complexes with ClipR-59 and Akt, use buffers containing 1% Triton X-100, 150 mM NaCl, 10 mM Tris-HCl (pH 7.4), 1 mM EDTA, 1 mM EGTA, 0.2 mM sodium orthovanadate, 0.5% NP-40, and protease inhibitors .

  • When studying GTPase interactions (RHOG, ARL4A), include GTP analogs like GMPPNP to stabilize interactions .

• Experimental controls:

  • Always include control IgG (matching the host species of the primary antibody) to identify non-specific binding .

  • Include input samples (5-10% of total lysate) to confirm protein expression levels .

  • For protein complex analysis, verify the presence of all components (e.g., ELMO2, ClipR-59, and Akt) in input samples by immunoblotting .

• Validation of results:

  • Perform reciprocal co-IPs (e.g., IP with anti-ClipR-59 followed by Western blotting for ELMO2, and vice versa) to confirm interactions .

  • Use GST pull-down assays with recombinant proteins as an alternative approach to validate interactions identified by IP .

  • Confirm functionality of identified interactions through knockdown/rescue experiments .

• Quantitative analysis:

  • Quantify band intensities from co-IP experiments to assess how experimental conditions (e.g., insulin stimulation) or mutations (e.g., in RBD or EID domains) affect complex formation .

  • Express results as fold change relative to appropriate controls (e.g., unstimulated conditions or wild-type protein).

Following these optimization steps enables researchers to reliably detect ELMO2 protein complexes and characterize their roles in various cellular processes, from insulin signaling to cytoskeletal remodeling.

What methodologies are available for studying ELMO2 conformational changes in vivo?

Investigating ELMO2 conformational changes in vivo requires specialized techniques that can detect the closed versus open states of the protein:

• Genetically modified mouse models:

  • Generate knock-in mouse lines with specific mutations that alter ELMO2 conformation:

    • L43A mutation in the RBD (RBD/RBD) to abolish binding to RHOG/ARL4A, reducing signaling output .

    • I196D mutation in the EID (EID/EID) to favor the open conformation, increasing signaling output .

  • Validate these mutations through molecular techniques and functional assays in the resulting tissues/cells .

• Biochemical validation methods:

  • NMR spectroscopy: Use 15N-labeled proteins (e.g., GMPPNP-loaded RHOG) to monitor line-broadening upon titration with wild-type versus mutant ELMO2, confirming binding disruption in RBD mutants .

  • Isothermal titration calorimetry (ITC): Measure binding affinities between ELMO2 variants and interaction partners (e.g., 10.3 μM for RHOG-WT ELMO2, no measurable binding for L43A mutant) .

  • Analyze Cryo-EM structures of ELMO-DOCK complexes to predict and validate how mutations might affect conformation .

• Monomolecular biosensors:

  • Develop fluorescence-based biosensors that report on ELMO2 conformational states .

  • These can be used in live-cell imaging to monitor real-time conformational changes in response to stimuli.

• Functional validation in tissue contexts:

  • Analyze phenotypic outcomes in mutant mouse models after specific challenges:

    • For muscle regeneration: Use cardiotoxin (CTX) injections to induce injury, then measure myofiber size and nuclei count at different timepoints (7, 14, 21 days post-injury) .

    • For embryonic development: Examine skeletal muscle formation in embryos at specific stages (E14.5, E16.5) .

• Immunohistochemical analysis:

  • Use antibodies that recognize specific ELMO2 conformations or total ELMO2 to analyze protein localization in tissue sections .

  • Combine with markers for specific cell types (e.g., PAX7 for satellite cells) to assess cell-specific effects .

These methodologies provide complementary approaches to understanding how ELMO2 conformational changes affect its function in vivo, with implications for therapeutic targeting of ELMO2-dependent pathways in muscle regeneration and other contexts.

How can researchers validate ELMO2 antibody specificity for their experiments?

Validating ELMO2 antibody specificity is crucial for generating reliable research data. Researchers should implement the following comprehensive validation strategies:

• Knockdown/knockout controls:

  • Use shRNA or CRISPR-Cas9 to reduce or eliminate ELMO2 expression .

  • Confirm knockdown efficiency by Western blotting, expecting reduced band intensity at approximately 80 kDa .

  • The remaining signal after efficient knockdown represents either incomplete knockdown or non-specific binding.

• Rescue experiments:

  • Re-express shRNA-resistant ELMO2 in knockdown cells and verify restored protein levels .

  • Compare band patterns and intensities between wild-type, knockdown, and rescued samples.

  • This approach confirms that observed phenotypes are specific to ELMO2 depletion rather than off-target effects.

• Peptide competition assays:

  • Pre-incubate antibodies with the immunizing peptide before application to Western blots or tissues.

  • Specific binding should be blocked by the peptide, while non-specific binding will persist.

  • For antibodies like those targeting the C-terminus of human ELMO2, use synthetic peptides from the aa 700 to C-terminus region .

• Cross-reactivity assessment:

  • Test antibodies on samples from multiple species if working with cross-species models.

  • Confirm that the antibody detects ELMO2 in mouse, rat, and human samples as expected .

  • Evaluate potential cross-reactivity with ELMO1 or ELMO3, which share sequence homology with ELMO2.

• Application-specific validation:

  • For immunofluorescence: Compare staining patterns with different ELMO2 antibodies and correlate with known subcellular localization patterns .

  • For immunoprecipitation: Verify enrichment of ELMO2 in IP samples compared to input and check for co-precipitation of known interaction partners like DOCK1 .

  • For immunohistochemistry: Include appropriate positive and negative tissue controls and compare with RNA expression databases .

Implementing these validation strategies ensures that experimental findings are truly reflective of ELMO2 biology rather than antibody artifacts or technical limitations.

What are common technical challenges when working with ELMO2 antibodies?

Researchers working with ELMO2 antibodies may encounter several technical challenges that can affect experimental outcomes. Here are common issues and methodological solutions:

• Detection of protein complexes:

  • Challenge: ELMO2 functions in multi-protein complexes (e.g., with DOCK1, RHOG, ClipR-59, Akt), which can mask antibody epitopes .

  • Solution: Use mild lysis conditions that preserve complexes but allow antibody access. For co-immunoprecipitation, try different antibodies targeting various ELMO2 epitopes or use tagged versions where appropriate .

• Conformation-dependent epitope accessibility:

  • Challenge: ELMO2's closed and open conformations may affect antibody binding, particularly for antibodies targeting regions involved in conformational changes .

  • Solution: When studying conformational mutants (e.g., EID/EID or RBD/RBD), verify antibody reactivity with both conformations using recombinant proteins. Consider using antibodies targeting stable regions unaffected by conformational changes .

• Low endogenous expression levels:

  • Challenge: ELMO2 may be expressed at low levels in some cell types, making detection difficult.

  • Solution: Enrich samples through immunoprecipitation before Western blotting, use signal amplification methods like HRP-conjugated secondary antibodies, or consider more sensitive detection methods like chemiluminescence with extended exposure times .

• Specificity across ELMO family members:

  • Challenge: ELMO1 and ELMO2 share sequence similarity, potentially causing cross-reactivity.

  • Solution: Validate antibody specificity using samples from ELMO1 or ELMO2 knockout models. For co-expression contexts, use epitope tags to distinguish between family members .

• Detection of post-translational modifications:

  • Challenge: Post-translational modifications may alter antibody recognition or protein mobility on gels.

  • Solution: Use phosphatase treatment controls when studying phosphorylation-dependent events; consider using modification-specific antibodies when available.

• Membrane translocation studies:

  • Challenge: Detecting ELMO2 translocation to membranes upon stimulation (e.g., insulin) requires careful fractionation.

  • Solution: Use established plasma membrane isolation protocols and include appropriate membrane markers (e.g., syntaxin 4) and cytosolic markers to confirm fraction purity .

Addressing these technical challenges through methodological optimization enables more reliable investigation of ELMO2 biology across diverse experimental contexts.

How do you interpret ELMO2 antibody data in the context of protein-protein interactions?

Interpreting ELMO2 antibody data in protein-protein interaction studies requires careful analysis and consideration of multiple factors:

• Co-immunoprecipitation data interpretation:

  • Compare band intensities between experimental conditions and controls (e.g., unstimulated vs. insulin-stimulated) .

  • Assess relative enrichment of interaction partners (e.g., ClipR-59, Akt) in ELMO2 immunoprecipitates compared to control IgG pull-downs .

  • Verify reciprocal interactions by performing reverse co-IPs (e.g., immunoprecipitate with anti-Akt and detect ELMO2) .

  • Example interpretation: "The presence of Akt in anti-ClipR-59 immunoprecipitates and its reduction upon ELMO2 knockdown indicates that ELMO2 enhances the association between ClipR-59 and Akt" .

• Functional validation of interactions:

  • Correlate interaction data with functional outcomes (e.g., Glut4 translocation, glucose uptake) .

  • Establish causality through knockdown and rescue experiments, demonstrating that restored protein interactions correspond with rescued function .

  • Example framework: "Reintroducing shRNA-resistant ELMO2 into knockdown cells rescued both Akt-ClipR-59 interaction and insulin-stimulated Glut4 translocation, confirming the functional significance of this interaction" .

• Interpreting mutation effects on interactions:

  • For domain-specific mutations (e.g., RBD, EID), compare interaction profiles with wild-type ELMO2 .

  • Use quantitative techniques like isothermal titration calorimetry to measure binding affinities (e.g., 10.3 μM for RHOG and WT ELMO2, no detectable binding for L43A mutant) .

  • Correlate binding changes with structural data (e.g., NMR spectroscopy showing minimal line-broadening for L43A mutant) .

• Analysis across experimental systems:

  • Compare interaction data from different techniques (co-IP, GST pull-down, NMR) .

  • Validate findings across different cell types or model systems when possible.

  • Consider how tissue context might affect interactions (e.g., muscle cells vs. adipocytes) .

• Compartment-specific interactions:

  • Distinguish between cytosolic and membrane-associated interaction complexes through proper fractionation .

  • Correlate protein translocation (e.g., Akt to membrane) with complex formation and functional outcomes .

  • Example finding: "Insulin stimulation increased membrane-associated Akt in wild-type but not in ELMO2 knockdown cells, correlating with reduced Glut4 translocation" .

By applying these analytical approaches, researchers can derive meaningful insights from ELMO2 antibody data in the context of protein interactions, advancing understanding of signaling networks in insulin response, muscle development, and cell motility.

How can ELMO2 antibodies be used to investigate therapeutic potential in muscle disorders?

ELMO2 antibodies offer valuable tools for exploring therapeutic applications in muscle disorders based on ELMO2's established role in myoblast fusion and muscle regeneration:

• Monitoring therapeutic interventions targeting ELMO2 conformation:

  • Use ELMO2 antibodies to track changes in protein conformation and localization after drug treatment or gene therapy approaches .

  • Assess whether interventions successfully promote the open (active) conformation of ELMO2 in muscle tissues from disease models.

  • Correlate conformational changes with improvements in myoblast fusion and muscle regeneration capacity .

• Biomarker development for treatment response:

  • Employ ELMO2 antibodies in immunohistochemistry to assess changes in ELMO2 expression or localization patterns in muscle biopsies before and after therapy .

  • Correlate ELMO2 status with clinical outcomes and muscle regeneration metrics.

  • Example application: Using ELMO2 antibodies to track protein expression in satellite cells (PAX7-positive) during regeneration following therapeutic intervention .

• Assessing cell-based therapies:

  • For myoblast transplantation approaches, use ELMO2 antibodies to evaluate fusion capacity of donor cells .

  • In genetically modified cell therapies (e.g., with ELMO2 EID mutation), confirm protein expression and localization before and after transplantation .

  • Methodological approach: Combine ELMO2 immunostaining with fiber type markers and nuclei counts to assess fusion efficiency in regenerating areas .

• Target validation in disease models:

  • Apply ELMO2 antibodies to characterize protein expression and function in models of muscular dystrophies, age-related sarcopenia, or injury-induced muscle atrophy .

  • Validate therapeutic hypotheses by examining how disease states affect ELMO2 expression, localization, or conformational state.

  • Research question example: "Does the ELMO2 EID/EID mutation improve regeneration outcomes in mdx mice (Duchenne muscular dystrophy model)?"

• Monitoring inflammatory responses during therapy:

  • Use ELMO2 antibodies in combination with markers of inflammation (e.g., F4/80 for macrophages) to assess how ELMO2-targeted interventions affect the inflammatory phase of muscle repair .

  • This is particularly relevant since studies show comparable macrophage infiltration in ELMO2 EID/EID mutants at 3 days post-injury .

These research applications demonstrate how ELMO2 antibodies can facilitate the translation of basic discoveries about ELMO2's role in muscle biology into therapeutic approaches for muscle disorders characterized by impaired regeneration or excessive fibrosis.

What emerging techniques can enhance ELMO2 antibody-based research?

Several cutting-edge techniques are emerging that can significantly advance ELMO2 antibody-based research:

• Proximity-dependent labeling with ELMO2 antibodies:

  • Combine ELMO2 antibodies with proximity labeling methods like BioID or APEX2 to identify novel interacting partners in different conformational states.

  • This approach can reveal context-specific ELMO2 interactomes, such as those specific to insulin stimulation or during myoblast fusion .

  • Methodological advantage: Captures transient or weak interactions that might be missed by traditional co-immunoprecipitation.

• Super-resolution microscopy:

  • Apply techniques like STORM, PALM, or STED with ELMO2 antibodies to visualize protein localization at nanometer resolution.

  • This enables precise tracking of ELMO2 distribution during membrane recruitment, cell migration, or myoblast fusion events .

  • Example application: Mapping ELMO2-DOCK1-Rac1 complex formation at specific subcellular locations during directional migration.

• Single-cell proteomics and phosphoproteomics:

  • Use ELMO2 antibodies in single-cell mass cytometry (CyTOF) or imaging mass cytometry to analyze protein expression and phosphorylation across heterogeneous cell populations.

  • This reveals cell-to-cell variability in ELMO2 signaling within tissues undergoing regeneration or in disease states .

  • Research question example: "How does ELMO2 phosphorylation status differ between fusion-competent and quiescent myoblasts?"

• Conformation-specific antibodies:

  • Develop antibodies that specifically recognize the open or closed conformations of ELMO2.

  • These tools would enable direct monitoring of ELMO2 activation states in response to stimuli or in disease contexts .

  • Application: Use in high-throughput screening for compounds that stabilize the open (active) conformation for therapeutic development.

• In vivo intravital imaging:

  • Combine fluorescently labeled ELMO2 antibody fragments (Fabs) or nanobodies with intravital microscopy to track ELMO2 dynamics in living tissues.

  • This approach enables real-time visualization of ELMO2 activity during muscle regeneration or in response to therapeutic interventions .

  • Methodological consideration: Requires development of membrane-permeable antibody derivatives or genetic tagging strategies.

• CRISPR-based genomic tagging:

  • Use CRISPR/Cas9 to introduce epitope tags or fluorescent proteins at the endogenous ELMO2 locus.

  • When combined with specific antibodies, this allows tracking of endogenous ELMO2 without overexpression artifacts.

  • Example application: Creating knock-in reporter lines to monitor ELMO2 expression and localization during myoblast differentiation and fusion .

These emerging techniques, when properly optimized with validated ELMO2 antibodies, will provide unprecedented insights into ELMO2 biology and accelerate the development of therapeutic approaches targeting ELMO2-dependent pathways.

How can researchers investigate the crosstalk between ELMO2 and other signaling pathways?

Investigating crosstalk between ELMO2 and other signaling pathways requires sophisticated experimental approaches using ELMO2 antibodies:

• Multi-parameter co-immunoprecipitation:

  • Use ELMO2 antibodies to precipitate protein complexes under different stimulation conditions (e.g., insulin, growth factors, cytokines) .

  • Analyze precipitates by mass spectrometry to identify context-specific interaction partners.

  • Example approach: Compare ELMO2 interactomes in cells treated with insulin versus platelet-derived growth factor to identify pathway-specific versus shared components.

  • Methodological consideration: Use quantitative proteomics (SILAC, TMT) for rigorous comparison across conditions .

• Phosphorylation dynamics analysis:

  • Immunoprecipitate ELMO2 from cells stimulated with pathway activators and analyze phosphorylation status.

  • Correlate ELMO2 phosphorylation with its conformational state and activity in different signaling contexts .

  • Research question example: "Does insulin-stimulated phosphorylation of ELMO2 affect its interaction with RHOG or DOCK proteins?"

  • Technical approach: Combine phospho-specific antibodies with ELMO2 antibodies in sequential immunoprecipitation experiments.

• Pathway inhibitor studies:

  • Treat cells with specific inhibitors of known pathways (e.g., PI3K/Akt, MAPK, Wnt) and assess effects on:

    • ELMO2 subcellular localization using immunofluorescence

    • ELMO2 protein interactions using co-immunoprecipitation

    • ELMO2-dependent functional outcomes like Glut4 translocation or myoblast fusion

  • This approach identifies upstream regulators and downstream effectors of ELMO2 signaling.

• Genetic manipulation combined with pathway analysis:

  • Express conformational mutants of ELMO2 (RBD/RBD or EID/EID) and analyze effects on multiple signaling pathways using phospho-specific antibody arrays or targeted proteomics .

  • Compare signaling profiles between wild-type and mutant ELMO2-expressing cells to identify pathways differentially affected by ELMO2 conformation.

  • Example finding: "ELMO2 EID/EID mutation enhances not only Rac1 activation but also affects mTOR signaling in regenerating muscle fibers."

• Temporal analysis of signaling integration:

  • Use ELMO2 antibodies in time-course experiments following stimulus application to track:

    • Changes in ELMO2 complex formation over time

    • Correlation with activation kinetics of other pathways

    • Sequential phosphorylation or other post-translational modification events

  • This reveals how ELMO2 participates in signaling integration over time.

• Tissue-specific signaling interactions:

  • Compare ELMO2 signaling partners between different tissues (e.g., muscle versus adipose tissue) using tissue-specific pull-downs with ELMO2 antibodies .

  • Identify tissue-specific adaptors or regulators that may direct ELMO2 function toward particular pathways.

  • Research application: "Identifying tissue-specific ELMO2 regulators could enable targeted therapeutic approaches for muscle disorders without affecting ELMO2 function in other tissues."

These methodological approaches, centered on the use of ELMO2 antibodies, provide a comprehensive framework for investigating how ELMO2 integrates and communicates with diverse signaling networks in physiological and pathological contexts.